Trading Signals: AUTL Stock Price Prediction and Forecast (Fri. Jun. 22, 2018 - Fri. May. 13, 2022)(Autolus Therapeutics plc )
| AUTL latest price $5.4300 (0.18%) ($5.0500 - $5.6200) on Thu. Apr. 2, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 6.71% (three month average) | RSI | 51 | Latest Price | $5.4300(0.18%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | AUTL declines -0.7% a day on average for past five trading days. | Weekly Trend | AUTL advances 6.4% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Growth stock rally for small cap. | Correlated ETFs | Broad market will support AUTL advance at 0% a week (0% probability) CEMB(10%) XLV(10%) XLB(9%) DIA(8%) EMHY(8%) | Factors Impacting AUTL price | AUTL will decline at least -3.355% in a week (0% probabilities). SHY(-7%) BWX(-7%) TLT(-4%) VXX(-3%) BNDX(-3%) | | | | | Relative Volatility | | | | Market Trend Strength | -3.355% (StdDev 6.71%) | Hourly BBV | 0 () | Intraday Trend | 0.2% | | | |
|
Resistance Level | $5.58 | 5 Day Moving Average | $5.58(-2.69%) | 10 Day Moving Average | $5.25(3.43%) | 20 Day Moving Average | $5.58(-2.69%) | To recent high | -58.2% | To recent low | 6.3% | Market Cap | $284m | | | | Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm's portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom. |